Polifarmasi dan Potensi Interaksi Obat pada Pasien Geriatri dengan Diabetes Melitus Tipe 2 dan Hipertensi di Instalasi Rawat Inap Rumah Sakit Kilisuci Kota Kediri

Abstract View: 30,
Download: 27

Authors

  • Anis Dhafin Universitas Kadiri
  • Elsa Mahardika Putri Universitas Kadiri
  • Herman Herman Universitas Kadiri
  • Pulung Prabowo Universitas Kadiri
  • Nur Fahma Laili Program Studi Profesi Apoteker, Fakultas Ilmu Kesehatan, Universitas Kadiri

DOI:

https://doi.org/10.32665/faskes.v4i1.6853

Keywords:

Diabetes Melitus Tipe 2; Geriatri; Hipertensi; Interaksi Obat; Polifarmasi

Abstract

Latar belakang: Pasien geriatri dengan diabetes melitus tipe 2 dan hipertensi berisiko mengalami polifarmasi dan potensi interaksi obat. Tujuan: Mengidentifikasi karakteristik pasien, kejadian polifarmasi, potensi interaksi obat, tingkat keparahan interaksi, serta hubungan polifarmasi dengan potensi interaksi obat. Metode: Penelitian observasional analitik retrospektif ini menggunakan data rekam medis pasien rawat inap Rumah Sakit Kilisuci Kota Kediri tahun 2025. Sampel dipilih secara purposive berdasarkan kriteria usia ≥60 tahun dan kelengkapan data terapi, sehingga diperoleh 34 pasien. Potensi interaksi obat dianalisis menggunakan Medscape Drug Interaction Checker, dikonfirmasi dengan Drugs.com, serta diperkuat melalui DailyMed dan literatur ilmiah. Hubungan polifarmasi dengan potensi interaksi obat diuji menggunakan Fisher’s exact test. Hasil: Polifarmasi ditemukan pada 82,4% pasien. Potensi interaksi obat ditemukan pada 52,9% pasien dengan total 32 pasangan interaksi. Interaksi kategori moderate mendominasi, sedangkan major ditemukan pada sebagian kecil kasus. Tidak terdapat hubungan bermakna antara polifarmasi dan potensi interaksi obat. Simpulan dan saran: Potensi interaksi obat masih sering ditemukan. Medication review oleh farmasis perlu diperkuat dengan mempertimbangkan jenis obat, kondisi klinis, fungsi ginjal, dan risiko individual pasien.

References

American Diabetes Association Professional Practice Committee. (2025). 13. Older adults: Standards of care in diabetes-2025. Diabetes Care, 48(Supplement 1), S266-S282. https://doi.org/10.2337/dc25-S013

American Geriatrics Society Beers Criteria® Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 71(7), 2052-2081. https://doi.org/10.1111/jgs.18372

Azyenela, L., Pameswari, P., & Fatimah, N. (2025). Potensi interaksi obat pada pasien geriatri dengan diabetes melitus tipe-2 dan hipertensi di RSUP Dr. M. Djamil Padang. Jurnal Mandala Pharmacon Indonesia, 11(2), 327-334. https://doi.org/10.35311/jmpi.v11i2.820

de Boer, I. H., Khunti, K., Sadusky, T., Tuttle, K. R., Neumiller, J. J., Rhee, C. M., Rosas, S. E., Rossing, P., & Bakris, G. (2022). Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association and Kidney Disease: Improving Global Outcomes. Diabetes Care, 45(12), 3075-3090. https://doi.org/10.2337/dci22-0027

Doumat, G., Daher, D., Itani, M., Abdouni, L., El Asmar, K., & Assaf, G. (2023). The effect of polypharmacy on healthcare services utilization in older adults with comorbidities: A retrospective cohort study. BMC Primary Care, 24, Article 120. https://doi.org/10.1186/s12875-023-02070-0

Drugs.com. (2025, November 5). Drug interaction checker: Find unsafe combinations. Retrieved May 23, 2026, from https://www.drugs.com/drug_interactions.html

Drugs.com. (n.d.-a). Amlodipine and ketorolac interactions. Retrieved May 23, 2026, from https://www.drugs.com/drug-interactions/amlodipine-with-ketorolac-172-0-1415-0.html

Drugs.com. (n.d.-b). Glimepiride and levofloxacin interactions. Retrieved May 23, 2026, from https://www.drugs.com/drug-interactions/glimepiride-with-levofloxacin-1176-0-1457-0.html

Drugs.com. (n.d.-c). Spironolactone and valsartan interactions. Retrieved May 23, 2026, from https://www.drugs.com/drug-interactions/spironolactone-with-valsartan-2105-0-2288-0.html

Faisal, S., Khotib, J., Wibisono, C., Hamidah, K. F., Utomo, F. N., & Zairina, E. (2025). Factors contributing to the prevalence of potential drug-drug interactions among hospitalized elderly patients in a tertiary hospital in Eastern Java, Indonesia. Medical Journal of Indonesia, 34(3), 174-180. https://doi.org/10.13181/mji.oa.257888

Ilmi, P. N., Fauziah, H., & Muti, A. F. (2022). Prevalence of potential drug-drug interactions among Prolanis type 2 diabetes patient with hypertension in primary health care: Cross-sectional study. Journal of Research in Pharmacy and Pharmaceutical Sciences, 1(2), 66-73. https://doi.org/10.33533/jrpps.v1i2.6260

International Diabetes Federation. (2025). IDF Diabetes Atlas (11th ed.). https://diabetesatlas.org/

KDIGO. (2022). KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International, 102(5S), S1-S127. https://doi.org/10.1016/j.kint.2022.06.008

Medscape. (n.d.). Drug interaction checker. Retrieved May 23, 2026, from https://reference.medscape.com/drug-interactionchecker

Perkumpulan Endokrinologi Indonesia. (2024). Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 dewasa di Indonesia 2024. PB PERKENI.

U.S. National Library of Medicine. (n.d.-a). About DailyMed. DailyMed. Retrieved May 23, 2026, from https://dailymed.nlm.nih.gov/dailymed/about-dailymed.cfm

U.S. National Library of Medicine. (n.d.-b). Ketorolac tromethamine tablet: Drug label information. DailyMed. Retrieved May 23, 2026, from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40d145e6-13f7-41ac-e054-00144ff8d46c

U.S. National Library of Medicine. (n.d.-c). Ciprofloxacin tablet: Drug label information. DailyMed. Retrieved May 23, 2026, from https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=26e2d370-f59c-40ae-9c1e-7f8bf1f9fde4

U.S. National Library of Medicine. (n.d.-d). Ondansetron tablet: Drug label information. DailyMed. Retrieved May 23, 2026, from https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=834bc56a-657d-4733-9a60-47040cb5c7bf

U.S. National Library of Medicine. (n.d.-e). Spironolactone tablet: Drug label information. DailyMed. Retrieved May 23, 2026, from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4239da9e-dd0c-9af0-e063-6394a90a3cbb

U.S. National Library of Medicine. (n.d.-f). Levofloxacin tablet: Drug label information. DailyMed. Retrieved May 23, 2026, from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec61dd9d-a016-4740-b9b8-20754e50be98

Varghese, D., Ishida, C., & Koya, H. H. (2024). Polypharmacy. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK532953/

World Health Organization. (2021). Guideline for the pharmacological treatment of hypertension in adults. World Health Organization. https://www.who.int/publications/i/item/9789240033986

Downloads

Published

21.07.2026
Abstract View: 30, PDF Download: 27